21 research outputs found
Breast cancer-specific quality of life (EORTC QLQ-BR23) scores between CAM users and non-CAM users <sup>a</sup>.
<p><sup>a</sup> Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p><sup>b</sup> 58 sexually active patients responded</p><p><sup>c</sup> 125 sexually active patients responded</p><p>*Significance level at <i>p</i> < 0.05</p><p>Breast cancer-specific quality of life (EORTC QLQ-BR23) scores between CAM users and non-CAM users <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t005fn001" target="_blank"><sup>a</sup></a>.</p
Factors associated with high and low global health status (QOL) (N = 308)<sup>a</sup><sup>,</sup><sup>b</sup>.
<p><sup>a</sup> Other ethnic groups were excluded in the analysis</p><p><sup>b</sup> CAM modality used by less than 10% of CAM users was excluded from the analysis</p><p>* Significance level at <i>p</i> < 0.05</p><p>**Significance level at <i>p</i> < 0.01</p><p>***Significance level at <i>p</i> < 0.001</p><p>Factors associated with high and low global health status (QOL) (N = 308)<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t007fn001" target="_blank"><sup>a</sup></a><sup>,</sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t007fn002" target="_blank"><sup>b</sup></a>.</p
Quality of life (EORTC QLQ-C30) scores among CAM users<sup>a</sup>.
<p><sup>a</sup> Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p>*Significance level at <i>p</i> < 0.05</p><p>Quality of life (EORTC QLQ-C30) scores among CAM users<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t004fn001" target="_blank"><sup>a</sup></a>.</p
Quality of life (EORTC QLQ-C30) scores between CAM users and non-CAM users <sup>a</sup>.
<p><sup>a</sup> Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p>*Significance level at <i>p</i> < 0.05</p><p>Quality of life (EORTC QLQ-C30) scores between CAM users and non-CAM users <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t003fn001" target="_blank"><sup>a</sup></a>.</p
Breast cancer-specific quality of life (EORTC QLQ-BR23) scores among CAM users<sup>a</sup>.
<p><sup>a</sup> Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p><sup>b</sup> A total of 20 MBP users reported as being sexually active answered these</p><p><sup>c</sup> A total of 51 MBP-NP users reported as being sexually active answered these</p><p><sup>d</sup> A total of 39 MBP-NP-TM users reported as being sexually active answered these</p><p>*Significance level at <i>p</i> < 0.05</p><p>Breast cancer-specific quality of life (EORTC QLQ-BR23) scores among CAM users<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t006fn001" target="_blank"><sup>a</sup></a>.</p
The comparison of anxiety and depression scores between breast cancer patients with high or low perceived level of distress (N = 211).
<p>The comparison of anxiety and depression scores between breast cancer patients with high or low perceived level of distress (N = 211).</p
The correlation between changes in perceived distress with the changes in anxiety and depression scores among the breast cancer patients (N = 211).
<p>The correlation between changes in perceived distress with the changes in anxiety and depression scores among the breast cancer patients (N = 211).</p
Characteristics of the subjects (N = 221).
<p>Characteristics of the subjects (N = 221).</p
Patient, tumor characteristics and treatment along with the unadjusted Hazard Ratio for all cause mortality.
*<p>indicates valid proportions have been calculated (i.e., not considering unknown).</p